A recent study conducted at the Neuroscience and Neurotechnology Center of Excellence (NÖROM) investigates the therapeutic potential of non-invasive brain stimulation in Autism Spectrum Disorder (ASD). The research demonstrates that targeting brain plasticity through transauricular Vagal Nerve Stimulation (tVNS) significantly improves social deficits and restores neurodevelopmental markers in a valproic acid (VPA) mouse model.

Key Scientific Findings:

• Behavioral Restoration: The study utilized a battery of behavioral assays, including the Three-Chamber Test and Elevated Plus Maze. Results indicated that tVNS treatment significantly enhanced sociability and social preference indices while reducing anxiety-like behaviors in VPA-exposed mice, effectively counteracting the core behavioral deficits associated with ASD.
• Restoration of Neurogenesis: Histological and immunohistochemical analyses revealed that tVNS treatment reversed the VPA-induced reduction of critical neurogenic markers. Specifically, Brain-Derived Neurotrophic Factor (BDNF) and Doublecortin (DCX) expression levels were restored in the hippocampus, amygdala, and prefrontal cortex, suggesting a reinstatement of neuronal plasticity and proliferation.
• Neuroprotection and Apoptosis: The study identified elevated Caspase-3 immunoreactivity (an apoptosis marker) in the prefrontal cortex of the ASD model. tVNS intervention significantly downregulated Caspase-3 expression, indicating a neuroprotective mechanism that mitigates programmed cell death in cortical regions.

  Clinical Implications: These findings highlight the potential of tVNS as a non-invasive, neuromodulatory therapeutic intervention. By targeting the underlying neurobiological mechanisms—specifically neurogenesis and apoptotic pathways—tVNS offers a promising avenue for alleviating both the behavioral and physiological symptoms of ASD.

  https://onlinelibrary.wiley.com/doi/full/10.1002/dneu.23019